International Journal of Radiation Oncology * Biology * Physics
Volume 82, Issue 2 , Pages 739-742 , 1 February 2012

Phase I Clinical Trial Assessing Temozolomide and Tamoxifen With Concomitant Radiotherapy for Treatment of High-Grade Glioma

Presented at the 2005 American Society for radiation Oncology Annual Meeting.

  • Shilpen Patel, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Washington, Seattle, WA
    • Corresponding Author InformationReprint requests to: Shilpen Patel, M.D., Department of Radiation Oncology, University of Washington, 1959 Northeast Pacific Street, Box 356043, Seattle, WA 98195-6043. Tel: (206) 598-4100; Fax: (206) 598-3786
    • ,
  • Steven DiBiase, M.D.

      Affiliations

    • Robert Wood Johnson School of Medicine, Camden, NJ
    • ,
  • Barry Meisenberg, M.D.

      Affiliations

    • DeCesaris Cancer Institute, Annapolis, MD
    • ,
  • Todd Flannery, M.D.

      Affiliations

    • Princeton Radiation Oncology, Princeton, NJ
    • ,
  • Ashish Patel, M.D.

      Affiliations

    • Division of Radiation Oncology, Abington Memorial Hospital, Abington, PA
    • ,
  • Anil Dhople, M.D.

      Affiliations

    • MIMA Cancer Center, Melbourne, FL
    • ,
  • Sally Cheston, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Maryland, Baltimore, MD
    • ,
  • Pradip Amin, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Maryland, Baltimore, MD

Received 15 May 2010 ,Revised 22 December 2010 ,Accepted 31 December 2010.

References 

  1. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–710
  2. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123
  3. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003;30:10–14
  4. Stupp R, Mason WP, van den Bent MJ, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466
  5. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg. 1978;49:333–343
  6. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323–1329
  7. Pollack IF, Randall MS, Kristofik MP, et al. Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways. J Neurosurg. 1990;73:98–105
  8. Pollack IF, Randall MS, Kristofik MP, et al. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res. 1990;50:7134–7138
  9. Pollack IF, Kawecki S, Lazo JS. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg. 1996;84:1024–1032
  10. Baltuch GH, Couldwell WT, Villemure JG, et al. Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines: A comparison between staurosporine and tamoxifen. Neurosurgery. 1993;33:495–501
  11. O’Brian CA, Liskamp RM, Solomon DH, et al. Triphenylethylenes: A new class of protein kinase C inhibitors. J Natl Cancer Inst. 1986;76:1243–1246
  12. O’Brian CA, Liskamp RM, Solomon DH, et al. Inhibition of protein kinase C by tamoxifen. Cancer Res. 1985;45:2462–2465
  13. Vertosick FT, Selker RG, Randall MS, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and N-desmethyltamoxifen in vitro. J Neurooncol. 1994;19:97–103
  14. Mastronardi L, Farah JO, Puzzilli F, et al. Tamoxifen modulation of carboplatin cytotoxicity in a human U-138 glioma cell line. Clin Neurol Neurosurg. 1998;100:89–93
  15. Rohlff C, Blagosklonny MV, Kyle E, et al. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate. 1998;37:51–59
  16. da Rocha AB, Mans DR, Bernard EA, et al. Tamoxifen inhibits particulate-associated protein kinase C activity and sensitizes cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. Eur J Cancer. 1999;35:833–839
  17. Fine R. In: DiBiase S, editor; 2000.
  18. Donson AM, Weil MD, Foreman NK. Tamoxifen radiosensitization in human glioblastoma cell lines. J Neurosurg. 1999;90:533–536
  19. Akerley W, Herndon JE, Lyss AP, et al. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non–small-cell lung cancer: A limited-access study—CALGB 9534. Clin Lung Cancer. 2005;7:47–53
  20. Robins HI, Won M, Seiferheld WF, et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro-Oncology. 2006;8:47–52
  21. MacDonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–1280

 Conflict of interest: none.

PII: S0360-3016(11)00051-4

doi: 10.1016/j.ijrobp.2010.12.053

International Journal of Radiation Oncology * Biology * Physics
Volume 82, Issue 2 , Pages 739-742 , 1 February 2012

Article Tools